Medaffcon Provides Temporary Staffing Services Across the Nordics
An outsourced employee is a flexible solution for a company’s short-term resourcing need or for longer absence such as parental leave or sick leave.
All articles
-
-
Overall survival among SCT patients with multiple myeloma has improved between 2013 and 2022
This Finnish registry-based study investigated the development of treatment practices and patient outcomes between 2013 and 2022.
-
Preparing for the EHDS Era in Sweden Requires Major Investments
The European Health Data Space Regulation (EHDS) is set to transform the use of health data across Europe.
-
The Nordic countries join forces in HTA medicine assessments
The aim of the cooperation is to harmonize processes and produce joint assessments that each country can use in its own decision-making.
-
Up to 20–30 Percent of All Care May Be of Low Value to Patients
Eliminating low-value care is a key means of safeguarding the sustainability and quality of healthcare.
-
The Nordics Should Collaborate in the Life Science Sector
Access times to medicines vary greatly between European countries, and delays in oncology drugs in particular are increasing.
-
Unlocking Nordic Healthcare Data with Medaffcon
A Nordic approach to data collection carried out through Medaffcon saves clients’ resources, reduces duplicate work, and accelerates processes.
-
Ling Zhu Brings Versatile Expertise to the Data Team in Sweden
Medaffcon’s new data team member, Ling Zhu, works in Medaffcon’s Stockholm office.
-
Finland is Developing a Model for the Assessment and Reimbursement of Digital Therapies
Finland is developing a model to streamline the adoption of digital healthcare solutions.
-
Summer Greetings from our CEO
As summer approaches, it’s a great time to pause, reflect, and appreciate the progress we’ve made together.
-
Discussions on Fair Pricing of Medicines at the Swedish Health Economics Days
The Swedish Health Economics Association (SHEA) held its annual conference, offering valuable insights into key topics in health economics.
-
Target Trial Emulation brings the logic of randomized trials into real-world data
Target Trial Emulation does not replace randomized controlled trials, but it applies their logic and rigor to real-world data analysis.
-
Data Team is the Backbone of Medaffcon, Ensuring the Reliability of Research Results
The data team keeps Medaffcon's research projects on track and ensures that the research findings are scientifically sound. At the heart of the team’s work is the processing and analysis of patient data, particularly in Real-World Evidence (RWE) studies.
-
Sweden’s TLV Updates Reimbursement Model for Rare Diseases
Sweden has introduced a new reimbursement model for orphan drugs, likely to increase treatment options for rare diseases. At the same time, pharmaceutical companies are now expected to provide local evidence.
-
Medaffcon Presented Insights from Finnish Real-World Data at European Lung Cancer Congress
Medaffcon's European Lung Cancer Congress (ELCC) poster showcased key findings from a recent study on non-small cell lung cancer (NSCLC).
-
An Experienced Researcher seeks answers for their clients
Johan Rehnberg started working as a Scientific Advisor at Medaffcon’s Swedish office in August 2024. He is a dynamic researcher who values opportunities to learn new things and develop his skills – opportunities that Medaffcon provides.
-
Medaffcon’s Machine Learning Algorithm Adapts to Various Research Needs
The algorithm was originally developed to extract smoking status from patient texts with purpose to analyze the effects of smoking on postoperative complications. Today, it is also being utilized in lung cancer research.
-
Asthma and Antibiotic Use Increase the Risk of Revision Surgery in CRSwNP Patients
Asthma and antibiotic use are linked to a higher risk of revision surgery in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). This finding is based on a real-world evidence (RWE) study published in February.
-
The Demand for Outsourced Experts is Growing in Pharmaceutical Companies
Medaffcon provides skilled temporary workforce solutions for its client companies. An outsourced expert is a flexible solution to address a company's short-term resourcing challenges.
-
Medaffcon’s Market Access Team Prepares Nordic Projects under the Leadership of Simo Jääskeläinen
Medaffcon’s Market Access team welcomed a new leader in mid-November, as Simo Jääskeläinen returned to his familiar workplace after a six-year hiatus.
-
Prostate Cancer Study Successfully Linked Deep Clinical Hospital Data with Broader Healthcare Data
A real-world evidence (RWE) study on the treatment of metastatic castration-resistant prostate cancer (mCRPC) has provided new insights into the therapeutic strategies for mCRPC. The analysis was based on data from 2,500 patients treated in Finland.
-
Lymphoma Project by the University of Eastern Finland and Medaffcon Generates Over Ten Publications
The lymphoma research project has proven to be an exceptionally versatile source of new knowledge. The project includes at least two doctoral researchers, and its results are expected to generate well over ten scientific articles.
-
Extensive Finnish Study Offers New Insights into Infection Risk and Mortality in Multiple Myeloma
Multiple myeloma significantly increases the risk of infections. A recent real-world evidence (RWE) study revealed that multiple myeloma (MM) patients experience more infections compared to healthy controls, even prior to diagnosis. Infections, both before and after diagnosis, were associated with an increased mortality.
-
5th Nordic RWE and AI conference – 28-29 January 2025, Helsinki
5th Nordic RWE and AI conference is organized by University of Helsinki and Åbo Akademi University. Register to the event here!
-
RWE Study: Chronic Kidney Disease often goes undiagnosed
Despite its high-risk nature and availability of kidney treatments, chronic kidney disease (CKD) often goes undiagnosed. This especially concerns patients without type 2 diabetes (T2D), who represent the majority of CKD patients. This finding comes from a recent registry study published in Nephrology Dialysis Transplantation (NDT).
-
AI Brings New Opportunities to RWE Research – Its Use in Health Data Analysis is Limited
Artificial intelligence (AI) is transforming research and working life across various industries. But what is its significance in health data analysis and real-world evidence (RWE) research? Medaffcon’s experts, Juhani Aakko and Lisse-Lotte Hermansson, share their perspectives on AI in their work.
-
Insights from ISPOR Europe: Patients to Be Included in RWE Studies
Patient-centricity was one of the key themes at ISPOR Europe in Barcelona this November. Participants also discussed topics such as the use of Real-World Evidence (RWE) in Health Technology Assessment (HTA) and the significance of artificial intelligence. In this article, Medaffcon's ISPOR attendees share the most important themes from this year's event.
-
Payers Expect Clearer Demonstration of Health Technology Benefits
Sweden and Finland are leaders in developing and applying health technology and provide ideal environments for conducting Health Technology Assessments (HTA) for medical devices.
-
Medaffcon Brings RWE from the Nordic Markets for Global Use
Medaffcon's operations in Sweden are well-established and growing, offering pharmaceutical companies RWE studies and Market Access services delivered by Data Scientists, Market Access experts, and RWE specialists working together.
-
Prognosis for Multiple Myeloma has Improved, but Prevalence is Increasing
The prognosis for patients with multiple myeloma (MM) has improved as treatments have advanced, but the disease remains incurable. The prevalence of the disease is increasing in Finland as the population gets older. This is evident from a recently published nationwide retrospective study based on real-world evidence (RWE).
-
New Diabetes Medications Were Actively Adopted Between 2012–2019 – The Results Are Promising
The adoption of new diabetes medications in Finland was active between 2012 and 2019, according to an RWE (Real World Evidence) study published in May 2024. The study was conducted by Medaffcon in collaboration with the pharmaceutical company Sanofi.
-
Medaffcon is Preparing to Conduct RWE Studies in Neurology and Psychiatry
In the coming years, breakthroughs in neurological and psychiatric drug research are expected to change treatment practices and significantly improve patients’ quality of life.
-
Medaffcon’s scientific expert’s day includes a variety of activities tailored to the needs of the pharmaceutical industry
Medaffcon experts are versatile professionals who adapt to customer needs. In this article, one of them, Liisa Ukkola-Vuoti, a senior scientific advisor at Medaffcon, describes her work over two weeks. Liisa is also one of the writers for the Health Data Site by Medaffcon.
-
New RWE Study Indicates Poor Prognosis for NSCLC Patients Despite Targeted Therapies
Lung cancer is the leading cause of cancer deaths in Finland, with a particularly poor prognosis for non-small cell lung cancer (NSCLC). It is often diagnosed at an advanced stage when treatment options are limited. A recently published retrospective registry-based real-world evidence (RWE) study on KRAS-mutated NSCLC patients in Finland addressed this issue.
-
Medaffcon’s Patient Dynamics Tool Helps Focus and Find the Right Actions
Are you employed in the pharmaceutical industry and seeking insights into your product's position within the Finnish market? Then Patient Dynamics is the ideal tool for you. Developed by Medaffcon, Patient Dynamics caters to the needs of pharmaceutical companies by providing precise information for sales and marketing decision-making.
-
EHDS makes Finland an even more attractive place for RWE research
Finland will become an even more attractive place for conducting RWE (real-world evidence) research when it becomes a seamless part of the European Health Data Space (EHDS). Thus, health data can be used more efficiently across the European Union (EU), and datasets can be combined on an EU-wide basis.
-
The OMOP Data Model Helps Standardize Healthcare Data
A key challenge in using real-world healthcare data (RWD) is how to standardize data across different healthcare providers and countries.
-
The Real-World Data (RWD) from the HUS Data Lake Provides Clinicians with Valuable Information about Treatment Outcomes
Hospital data lakes offer clinicians diverse real-world data (RWD) that supports their work. Dr. Heikki Ekroos, Chief Physician of Pulmonary Diseases at Helsinki University Hospital (HUS) Porvoo Hospital, presented real-world evidence (RWE) studies that were based on HUS data lakes data at Medaffcon’s EMMA client event.
-
Sweden is a Rich Source of Real-World Evidence (RWE) and Health Data – Together with Finland, it Offers a Population of 15 Million
Real-world data (RWD) created in Finnish healthcare is comprehensive and high-quality. Sweden, another Scandinavian country, also offers high-quality healthcare data for real-world evidence generation.
-
Renewable drug therapy challenges the current complex drug evaluation system
“Renewable drug therapy challenges the current complex drug evaluation system,” states Lauri Pelkonen, a leading expert at the Ministry of Social Affairs and Health (STM). For this reason, the evaluation activity is being reformed to better respond to changes in the operating environment.
-
The EU introduces changes to the assessment of medicines: EU HTA application in evaluations will gradually start next year
The EU introduces changes to the assessment of medicines: EU HTA application in evaluations will gradually start next year
-
Finland: An Ideal Environment for the Pharmaceutical Industry’s Real-World Evidence (RWE) Studies
Pharmaceutical companies should consider Finland when evaluating locations for Real-World Evidence (RWE) studies. The country boasts numerous strengths that make it an outstanding choice for real-world data-based (RWD) research. “Finland’s strong tradition and extensive experience in utilizing healthcare registries for research make it unique,” says Dr. Riikka Mattila, Scientific Advisor at Medaffcon.
-
Heikki Koski Appointed as CEO of Medaffcon Oy
Heikki Koski, currently the Service Business and Development Director at Tamro, has been appointed as the CEO of Medaffcon Oy, effective from April 1, 2024. Medaffcon is a subsidiary of Tamro Oyj. The current CEO of Medaffcon, Jarmo Hahl, will continue to play a pivotal role in shaping the company's future in his new position leading the consulting business.
-
Medaffcon has in-depth Understanding of the Needs of the Pharmaceutical Industry
Selecting the right interactions is a key factor for success. Therefore, the client should also consider how well the partner understands the pharmaceutical industry's needs. When the partner has extensive hands-on experience from the industry, these irreplaceable insights enable the partner to guide the project at different strategic levels, ensuring that the client’s various needs can be identified and met.
-
The OMOP Common Data Model facilitates the utilization of healthcare data – Medaffcon was involved in a Finnish OMOP pilot study
In healthcare, there is a vast amount of data being generated and processed. Sometimes, its utilization is cumbersome because the data is scattered, and its analysis requires a lot of preprocessing.